A series of reports on the 8th China Hospital Pharmaceutical Policy Forum II: the new medical reform and the responsibility of pharmacists in China

Source: Hu Xin, director of the Pharmaceutical Department of Beijing hospital, China pharmaceutical innovation promotion association, made a report entitled "China's new medical reform and the responsibility of pharmacists" at the 8th hospital pharmaceutical Forum on July 24, 2017 He proposed that the new medical reform started in 2009 is the reform of medicine in front and medicine in the back In the early stage, through various "combination boxing" to strengthen drug control, in the face of the current situation, how can Chinese hospital pharmacists turn into butterflies? Hu Xin, director of the Pharmaceutical Department of Beijing hospital, is a kind of medicine and art In the past 100 years, the average life span of the global population has increased significantly, and drugs with the function of prevention and treatment of diseases have made great contribution However, the objective reality of China 's pharmaceutical industry and market is that generic drugs are mainly used, and systematic clinical research data are lacking, with single generic varieties, lack of hospital pharmacists, and low investment in drug research and development There are huge differences between Chinese and foreign clinical drug varieties We can see from the top 20 drug varieties with the highest clinical treatment amount at home and abroad In 2015, there is no same drug between the top 20 drugs with the highest treatment amount in China and the top 20 drugs with the highest treatment amount in the world The basic situation of drug use in Chinese medical institutions is that traditional Chinese medicine accounts for more than 40% of the sales volume of medical insurance drugs and 80% of the sales volume of Western medicine There are a large number of non first-line drugs or auxiliary drugs, and the use of drugs is seriously wasted; the role of pharmacists is not fully played He pointed out that rational use of drugs must be based on the fundamental principles of safety, effectiveness, economy and Appropriateness As for the role of pharmacists in rational drug use, he summarized the following aspects: pharmaceutical information service; comparative research and monitoring of drug effectiveness and safety; prescription audit and medical record investigation and comment on drug use; monitoring of adverse drug events and drug treatment errors; drug clinical trial research, design of individualized drug delivery scheme; pharmacist consultation clinic and multidisciplinary collaborative diagnosis and treatment Pattern He stressed that pharmacists must improve the knowledge and ability to apply big data and strengthen the awareness of risk management There is a huge gap between China and the international advanced level in pharmacovigilance China should also formulate corresponding drug risk management plan, which requires that the risk factors should be controlled at any stage of the whole life cycle of drugs, so as to achieve the balance of risk and benefit The development and implementation of risk management plan should be based on a strong pharmacovigilance database or adverse reaction monitoring database, in which pharmacists can play an important role Finally, he suggested that the measurement methods of pharmacists' social value and clinical value should be considered in multiple ways, such as how much loss of adverse reactions can be reduced by pharmacists' services every year, how much medical insurance cost can be reduced by pharmacists' "gatekeeping" and "quality control", how much medical accidents or disputes can be reduced by pharmacists' medical order review, how pharmacists can integrate into chronic disease management, community service and network service, and how pharmacists' services can be increased How much waste can patient compliance reduce? The role of pharmacists in the linkage of three medical services, the formulation of medical insurance payment standards, and the implementation of zero difference rate of drugs are discussed in detail.